Fortis Healthcare Limited announced the outcome of its Board meeting held on February 13, 2026, approving the Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The Board also approved the formulation of the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (“ESOP 2026” / “Scheme”), subject to shareholder approval, and a revision to the Related Party Transaction Policy.
Financial Performance for Q3 Ended December 31, 2025
The Board of Directors of Fortis Healthcare Limited, following deliberations on Friday, February 13, 2026, officially approved the results for the third quarter and the cumulative nine months ending December 31, 2025. The accompanying reports include the Limited Review Report from the Statutory Auditors for both standalone and consolidated figures.
Standalone Financial Highlights (Rupees in lacs)
Focusing on key standalone performance metrics for the quarter ended December 31, 2025:
- Revenue from operations: 44,293 lacs, compared to 45,581 lacs in the preceding quarter (Sep 30, 2025).
- Total expenses: Stood at 42,945 lacs.
- Net profit/(loss) from continuing operations (after tax): Reported as 2,840 lacs.
- Net profit/(loss) for the period (Total): 2,840 lacs.
- Basic Earnings Per Share (continuing operations, not annualised): 0.38 Rupees.
For the nine months ended December 31, 2025, the company recorded a Net profit/(loss) from continuing operations of 20,537 lacs.
Consolidated Financial Performance (Rupees in lacs)
On a consolidated basis, the Group’s results for the quarter ended December 31, 2025, demonstrated:
- Revenue from operations: 226,501 lacs, up from 233,144 lacs in Q2 FY2026.
- Total expenses: 196,524 lacs.
- Profit before tax from continuing operations: 26,568 lacs.
- Net profit/(loss) for the period (Total): 19,740 lacs.
- Basic Earnings Per Share (continuing operations, not annualised): 2.57 Rupees.
For the nine months ended December 31, 2025, the consolidated Net profit/(loss) for the period (Total) was 79,300 lacs, with Basic Earnings Per Share at 10.28 Rupees.
Approval of Employee Stock Option Scheme 2026
The Board, acting on the recommendation of the Nomination and Remuneration Committee meeting held on February 11, 2026, approved the implementation of the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (“ESOP 2026” / “Scheme”). This framework is established in compliance with the relevant SEBI regulations.
The proposed pool comprises 1,50,99,163 (One Crore Fifty Lakh Ninety-Nine Thousand One Hundred and Sixty-Three only) employee stock options. Each option entitles the holder to one fully paid-up equity share of face value of Rs. 10/-. The pricing formula dictates that the exercise price will equal the market price on the relevant date, provided it is not lower than the face value.
Policy Update and Legal Disclosures
The Board also approved a Revision in Related Party Transaction Policy, with the updated policy attached to the announcement. Furthermore, the financial results include detailed notes concerning ongoing investigations by regulatory authorities related to transactions prior to the reconstituted Board’s takeover in March 2018, detailing actions taken, provisions made (including a one-time impact of new Labour Codes amounting to Rs. 1,035 lacs on standalone results), and management’s confidence in the outcomes.
Source: BSE
